SLC5A2 and type 2 diabetes mellitus: Gürkan et al. reported that 6 months of dapagliflozin therapy decreased the serum levels of LDL-C and TGs in patients with type 2 diabetes mellitus (T2DM) [5], while Cha et al. found that SGLT2-i therapy for 24 weeks significantly increased HDL-C and LDL-C levels in patients with T2DM [6].